Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances
11.01.2026 - 17:33:04
Eli Lilly and Company has opened 2026 with a clear strategic push to diversify and strengthen its business. A significant acquisition, promising clinical trial results, and new technology partnerships collectively signal the pharmaceutical giant’s ambitious direction for the coming years.
Market sentiment toward Eli Lilly remains robust. Coverage from 27 analyst firms includes 18 “Buy” ratings and an additional five “Strong Buy” recommendations. The consensus price target stands at $1,169. Recent initiations include UBS with a $1,250 target and Leerink Partners, which set a $1,234 target on January 5.
This confidence is supported by strong financials. For the third quarter of 2025, the company reported earnings per share of $7.02, surpassing the consensus estimate of Read more...
